NASDAQ:ORMP - Oramed Pharmaceuticals Stock Price, Forecast & News

Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."

Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) announced its quarterly earnings results on Thursday, January, 9th. The biotechnology company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.11. The biotechnology company had revenue of $0.67 million for the quarter. Oramed Pharmaceuticals had a negative net margin of 297.30% and a negative return on equity of 38.51%. View Oramed Pharmaceuticals' Earnings History.

Oramed Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, April 8th 2020. View Earnings Estimates for Oramed Pharmaceuticals.

2 brokers have issued 12 month target prices for Oramed Pharmaceuticals' stock. Their forecasts range from $7.00 to $20.00. On average, they anticipate Oramed Pharmaceuticals' share price to reach $13.50 in the next twelve months. This suggests a possible upside of 149.5% from the stock's current price. View Analyst Price Targets for Oramed Pharmaceuticals.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oramed Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oramed Pharmaceuticals.

Media coverage about ORMP stock has trended neutral this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Oramed Pharmaceuticals earned a media sentiment score of 0.5 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an effect on the stock's share price in the near term. View News Stories for Oramed Pharmaceuticals.

Oramed Pharmaceuticals saw a decline in short interest in December. As of December 31st, there was short interest totalling 448,700 shares, a decline of 23.5% from the December 15th total of 586,300 shares. Based on an average daily volume of 210,900 shares, the days-to-cover ratio is currently 2.1 days. Currently, 3.4% of the shares of the company are short sold. View Oramed Pharmaceuticals' Current Options Chain.

Some companies that are related to Oramed Pharmaceuticals include AMAG Pharmaceuticals (AMAG), Merus (MRUS), Kindred Biosciences (KIN), Lannett (LCI), 89bio (ETNB), Puma Biotechnology (PBYI), Recro Pharma (REPH), Evolus (EOLS), Avid Bioservices (CDMO), Mersana Therapeutics (MRSN), Spectrum Pharmaceuticals (SPPI), Syros Pharmaceuticals (SYRS), OptiNose (OPTN), Cue Biopharma (CUE) and INDIVIOR PLC/S (INVVY).

Based on aggregate information from My MarketBeat watchlists, some companies that other Oramed Pharmaceuticals investors own include TransEnterix (TRXC), Compugen (CGEN), Sarepta Therapeutics (SRPT), Inovio Pharmaceuticals (INO), Zynerba Pharmaceuticals (ZYNE), Pluristem Therapeutics (PSTI), Gilead Sciences (GILD), Novavax (NVAX), NovaBay Pharmaceuticals (NBY) and Caladrius Biosciences (CLBS).

Shares of ORMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ORMP stock can currently be purchased for approximately $5.41.

Oramed Pharmaceuticals has a market capitalization of $95.95 million and generates $2.70 million in revenue each year. The biotechnology company earns $-14,350,000.00 in net income (profit) each year or $0.82 on an earnings per share basis. View Additional Information About Oramed Pharmaceuticals.

The official website for Oramed Pharmaceuticals is http://www.oramed.com/.

Oramed Pharmaceuticals' mailing address is 1185 AVENUE SUITE 228, NEW YORK NY, 10036. The biotechnology company can be reached via phone at 844-967-2633 or via email at [email protected]